ENDRA Life Sciences Inc. (NDRA) |
|
1.535 0.025 (1.66%)
|
06-06 14:45 |
|
Open: |
1.57 |
Pre. Close: |
1.51 |
|
High:
|
1.6 |
Low:
|
1.5 |
|
Volume:
|
43,685 |
Market Cap:
|
11(M) |
|
|
|
Technical analysis |
as of: 2023-06-06 2:19:45 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
  |
| Target: |
Six months: 1.9 One year: 2.2 |
| Support: |
Support1: 1.21 Support2: 1 |
| Resistance: |
Resistance1: 1.63 Resistance2: 1.88 |
| Pivot: |
1.46  |
| Moving Average: |
MA(5): 1.47 MA(20): 1.44
MA(100): 2.82 MA(250): 4.28 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 60.5 %D(3): 54.1 |
| RSI: |
RSI(14): 47.1 |
| 52-week: |
High: 7.59 Low: 1.01 |
| Average Vol(K): |
3-Month: 43 (K) 10-Days: 37 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NDRA ] has closed below upper band by 36.6%. Bollinger Bands are 63.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.6 - 1.61 |
1.61 - 1.61 |
|
Low:
|
1.48 - 1.49 |
1.49 - 1.5 |
|
Close:
|
1.52 - 1.53 |
1.53 - 1.54 |
|
Company Description |
|
ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan. |
Headline News |
Thu, 01 Jun 2023
Can Fite Biofarmas Q1 Earnings Miss Estimated EPS by 1000 - Best Stocks
Mon, 15 May 2023
ENDRA Life Sciences Reports First Quarter 2023 Financial Results ... - Business Wire
Thu, 04 May 2023
ENDRA Life Sciences And 2 Other Stocks Under $2 Insiders Are Aggressively Buying - CURO Group Holdings (N - Benzinga
Tue, 02 May 2023
ENDRA Life Sciences Announces Closing of Public Offering and ... - Business Wire
Tue, 02 May 2023
Is ENDRA Life Sciences Inc (NDRA) Stock a Smart Value? - InvestorsObserver
Fri, 28 Apr 2023
ENDRA Life Sciences prices stock and warrants offering (NASDAQ ... - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Diagnostics & Research |
| Shares Out. |
7 (M) |
| Shares Float |
7 (M) |
|
% Held by Insiders
|
7.8 (%) |
|
% Held by Institutions
|
5.7 (%) |
|
Shares Short
|
34 (K) |
|
Shares Short P.Month
|
71 (K) |
Stock Financials |
|
EPS
|
-4 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.41 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-94.1 |
|
Return on Equity (ttm)
|
-195.6 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.76 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-12 (M) |
|
Levered Free Cash Flow
|
-7 (M) |
Stock Valuations |
|
PE Ratio
|
-0.38 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.06 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.93 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
